NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications: Summary and Recommendation for Future Research.


Journal

Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005

Informations de publication

Date de publication:
01 01 2021
Historique:
entrez: 11 12 2020
pubmed: 12 12 2020
medline: 16 7 2021
Statut: ppublish

Résumé

With potent antiretroviral therapy and simplified regimens, people living with HIV (PWH) are achieving near-normal lifespans but not necessarily a normal health span or healthy aging. PWH have a higher than expected risk of developing a number of non-AIDS comorbidities, coinfections, and complications (CCC), often against a background of stigma, poverty, and isolation. To gain a better understanding of research needs for HIV-associated CCC, the NIH convened a 2-day workshop (HIV-associated CCC, or HIV ACTION). A cross-institute NIH planning committee identified 6 key research areas: epidemiology and population research, pathogenesis and basic science research, clinical research, implementation science research, syndemics research and international research in low and middle income countries. Investigators were selected to lead working groups (WGs) to assess the state-of-the-art and identify 3-5 priority areas in each field before the workshop. A 2-day program at the NIH was developed which included presentations by invited experts and WG members. Over 400 participants attended the workshop. After general and individual WG discussions, the most pressing gaps, questions, or proposed action items were identified. Priority lists of pressing research issues were presented by cochairs of each WG. A detailed report is posted at the NHLBI website. This article reports the streamlined priority list and a summary of WG discussions to inform investigators of current priorities in the field. Collaborative efforts of many disciplines are needed to improve the health and wellbeing of PWH. Several common themes emerged across WG representing potential priorities for investigators and recommendations for the NIH.

Sections du résumé

BACKGROUND
With potent antiretroviral therapy and simplified regimens, people living with HIV (PWH) are achieving near-normal lifespans but not necessarily a normal health span or healthy aging. PWH have a higher than expected risk of developing a number of non-AIDS comorbidities, coinfections, and complications (CCC), often against a background of stigma, poverty, and isolation.
SETTING
To gain a better understanding of research needs for HIV-associated CCC, the NIH convened a 2-day workshop (HIV-associated CCC, or HIV ACTION).
METHODS
A cross-institute NIH planning committee identified 6 key research areas: epidemiology and population research, pathogenesis and basic science research, clinical research, implementation science research, syndemics research and international research in low and middle income countries. Investigators were selected to lead working groups (WGs) to assess the state-of-the-art and identify 3-5 priority areas in each field before the workshop. A 2-day program at the NIH was developed which included presentations by invited experts and WG members.
RESULTS
Over 400 participants attended the workshop. After general and individual WG discussions, the most pressing gaps, questions, or proposed action items were identified. Priority lists of pressing research issues were presented by cochairs of each WG. A detailed report is posted at the NHLBI website. This article reports the streamlined priority list and a summary of WG discussions to inform investigators of current priorities in the field.
CONCLUSION
Collaborative efforts of many disciplines are needed to improve the health and wellbeing of PWH. Several common themes emerged across WG representing potential priorities for investigators and recommendations for the NIH.

Identifiants

pubmed: 33306561
doi: 10.1097/QAI.0000000000002528
pii: 00126334-202101010-00002
pmc: PMC7982002
mid: NIHMS1674981
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-18

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL152957
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128156
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI073961
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027763
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States

Références

Legarth RA, Ahlström MG, Kronborg G, et al. Long-term mortality in HIV-infected individuals 50 Years or older: a nationwide, population-based cohort study. J Acquir Immune Defic Syndr. 2016;71:213–218.
Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810–818.
Wong C, Gange SJ, Moore RD, et al. Multimorbidity among persons living with human immunodeficiency virus in the United States. Clin Infect Dis. 2018;66:1230–1238.
Justice AC, Tate JP. Strengths and limitations of the veterans aging cohort study index as a measure of physiologic frailty. AIDS Res Hum Retroviruses. 2019;35:1023–1033.
Gabuzda D, Jamieson BD, Collman RG, et al. Pathogenesis of aging and age-related comorbidities in people with HIV: highlights from the HIV ACTION workshop. Pathog Immun. 2020;5:143–174.
Althoff KN, Gebo KA, Moore RD, et al. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV. 2019;6:e93–e104.
De Francesco D, Wit FW, Bürkle A, et al. Do people living with HIV experience greater age advancement than their HIV-negative counterparts?. AIDS. 2019;33:259–268.
Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787–1797.
Hawkins KL, Brown TT, Margolick JB, et al. Geriatric syndromes: new frontiers in HIV and sarcopenia. AIDS. 2017;31(suppl 2):S137–S146.
Lagathu C, Cossarizza A, Béréziat V, et al. Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers. AIDS. 2017;31(suppl 2):S105–S119.
Pallikkuth S, de Armas L, Rinaldi S, et al. T follicular helper cells and B cell dysfunction in aging and HIV-1 infection. Front Immunol. 2017;8:1380.
Pallikkuth S, de Armas LR, Rinaldi S, et al. Dysfunctional peripheral T follicular helper cells dominate in people with impaired influenza vaccine responses: results from the FLORAH study. PLoS Biol. 2019;17:e3000257.
Shankwitz K, Pallikkuth S, Sirupangi T, et al. Compromised steady-state germinal center activity with age in nonhuman primates. Aging Cell. 2020;19:e13087.
Justice JN, Ferrucci L, Newman AB, et al. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. Geroscience. 2018;40:419–436.
Chamie G, Hickey MD, Kwarisiima D, et al. Universal HIV testing and treatment (UTT) integrated with chronic disease screening and treatment: the SEARCH study. Curr HIV/AIDS Rep. 2020;17:315–323.
Womack JA, Justice AC. The OATH Syndemic: opioids and other substances, aging, alcohol, tobacco, and HIV. Curr Opin HIV AIDS. 2020;15:218–225.
Poteat T, Scheim A, Xavier J, et al. Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr. 2016;72(suppl 3):S210–S219.
Bhardwaj A, Kohrt BA. Syndemics of HIV with mental illness and other noncommunicable diseases: a research agenda to address the gap between syndemic theory and current research practice. Curr Opin HIV AIDS. 2020;15:226–231.
Bromberg DJ, Mayer KH, Altice FL. Identifying and managing infectious disease syndemics in patients with HIV. Curr Opin HIV AIDS. 2020;15:232–242.
Gamble-George JC, Longenecker CT, Webel AR, et al. ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): combatting chronic disease comorbidities in HIV populations through implementation research. Prog Cardiovasc Dis. 2020;63:79–91.
Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Curr Opin HIV AIDS. 2020;15:126–133.

Auteurs

Savita Pahwa (S)

University of Miami Miller School of Medicine, Miami, FL.

Steven Deeks (S)

University of California, San Francisco, CA.

Shimian Zou (S)

National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD.

Natalie Tomitch (N)

Office of AIDS Research (OAR), Bethesda, MD.

Leia Miller-Novak (L)

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD.

Elisabet Caler (E)

National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD.

Amy Justice (A)

Yale University School of Medicine, New Haven, CT.

Ned Sacktor (N)

Johns Hopkins University, School of Medicine, Baltimore, MD.

Dana Gabuzda (D)

Dana-Farber Cancer Institute, Boston, MA.

Peter W Hunt (PW)

University of California, San Francisco, CA.

Todd Brown (T)

Johns Hopkins University, School of Medicine, Baltimore, MD.

Ann Kurth (A)

Yale University, School of Nursing, Orange, CT.

Stefan Baral (S)

Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD.

Michael Mugavero (M)

University of Alabama at Birmingham, Birmingham, AL.

Kenneth H Mayer (KH)

Harvard University, Medical School and Fenway Health, Boston, MA.

Emily Mendenhall (E)

Georgetown University, Washington, DC.

Roger Detels (R)

University of California, Los Angeles, CA; and.

Vincent Mutabazi (V)

Regional Alliance Sustainable Development, Kigali, Rwanda.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH